Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington joined Proactive talk about the company's artificial intelligence venture which is being used to model respiratory syncytial virus (RSV).
It comes as its partner OneThree Biotech completed a tailored AI model using Poolbeg’s data gathered through a human challenge study into RSV.
Results from an analysis are expected later this year. This is the first time AI is being used to model RSV with complete longitudinal disease data.